Comment on "pP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"
Date
2019Journal
Science Translational MedicinePublisher
American Association for the Advancement of ScienceType
Article
Metadata
Show full item recordAbstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis. Copyright 2019 The Authors.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069912263&doi=10.1126%2fscitranslmed.aau0416&partnerID=40&md5=4dbc1da010bf94217da9296cc4c89105; http://hdl.handle.net/10713/10369ae974a485f413a2113503eed53cd6c53
10.1126/scitranslmed.aau0416